It has been reported that SIRT1 is upregulated in a spectrum of cancers, including lymphomas, leukemia and soft-tissue sarcomas, prostate cancer, lung cancer, and colon carcinoma via one or more of these targets [5–9]. Here, SIRT1 is linked to prostate cancer.